

Cell Therapy Manufacturing Asia

26-28 February 2020
Westin Miyako
Kyoto, Japan

THE ONLY CELL AND GENE THERAPY EVENT IN ASIA TO HELP YOU FAST TRACK MANUFACTURING & COMMERCIALIZATION ACROSS BORDERS

Delivering science, technologies and partners to accelerate stem cell, CAR-T and gene therapies to market

100+
attendees

160+
companies

79%
Asia based attendees

Brought to you by
informa connect

informaconnect.com/celltherapy-asia/

 @ NextGen365 #CELLTHERAPYASIA

CROSS-FERTILIZE IDEAS AND BEST PRACTICES WITH LEADERS FROM DIFFERENT DISCIPLINES

LATEST DATA, DEVELOPMENTS & CLINICAL RESULTS FOR IPSC, CAR-T AND OTHER NOVEL MOLECULES

- ▶ Push the boundaries of cell engineering, organ replacement & iPSc based regenerative medicine
- ▶ Understand the latest on enhanced quality & clinical results for CAR and T cell products
- ▶ Transition technologies from bench to bedside: CRISPR, Exosomes and more...

NOVEL TECH TRANSFER, PROCESS DEVELOPMENT & MANUFACTURING MODELS FOR COMMERCIAL SUCCESS

- ▶ Get to grips with technologies and novel platforms for efficient upstream and downstream processes
- ▶ Simplify manufacturing automation and prepare for commercialization
- ▶ Improve confidence in your raw material supply chain and analytical strategies

PRECISION MANUFACTURING, CDMO'S AND TECHNOLOGY EVALUATION – HOW & WHEN TO INNOVATE?

- ▶ Build a strategy for global commercial success with forward thinking in facility design and scalability
- ▶ Optimise the way you work with external partners to drive commercialization
- ▶ Prepare for successful delivery to patients & supply chain scale up

LEARN FROM LEADING INDUSTRY STAKEHOLDERS INCLUDING:



Hardy T S Kagimoto
Chairman & CEO
Healios K.K.,
Japan



Robin NG
Strategy Lead for Technology
and Manufacturing,
Cellular Biomedicine Group,
China



Wen Bo Wang
SVP, Technical Operations,
Fate Therapeutics, USA



Richard Wang
CEO,
Fosun Kite,
China

MAIN CONFERENCE • Thursday, February 27, 2020

7:30 *Registration*

7:55 **Conference Opening and Welcome**

STRATEGIES FOR GLOBAL COMMERCIAL SUCCESS – NOVEL TECH TRANSFER & MANUFACTURING MODELS ACROSS BORDERS

8:00 **Novartis/ Cellular Biomedicine Case Study – in China**

Robin Ng, Strategy Lead for Technology and Manufacturing, Cellular Biomedicine Group, *China*

8:30 **Experience with Yescarta in China**

Richard Wang, CEO, Fosun Kite, *China*

LATEST DATA & DEVELOPMENTS IN iPSC

9:00 **Cell Engineering & Organ Replacement**

- Engineering iPSC cells
- Cloaking/universal cells linked to iPSc

Hardy TS Kagimoto, Chairman and CEO, HealiOS K.K., *Japan*

9:30 **Consideration of standard specification and test methods for manufacturing of iPSC-MCB**

Takafusa Hikichi, Quality Control Unit Manager, Center for iPSC Cell Research and Application (CiRA), **Kyoto University**, *Japan*

10:00 **iPSCs-based Regenerative Medicine and Drug Development for CNS Diseases**

Hideyuki Okano, Team Leader, Laboratory for Marmoset Neural Architecture, **RIKEN Center for Brain Science**, Dean, **Keio University Graduate School of Medicine**, Professor and Chairman, Department of Physiology, **Keio University School of Medicine**, *Japan*

10:30 *Morning Coffee and Networking*

TECHNOLOGIES AND NOVEL PLATFORMS FOR EFFICIENT UPSTREAM AND DOWNSTREAM PROCESSES

11:00 **Manufacturing technologies for fulfilling the cell and gene therapy needs in Asia**

Colby Colasanto, Strategic Business Director, **Cellogics**, *Singapore*

11:30 **CAR-NK cell line manufacturing**

Sae Won Kim, Head of Immune Cell Therapy Team, **SL BIGN**, *South Korea*

12:00 **Spotlight Presentation – PBS Biotech**

12:30 *Lunch and Networking*

TECHNOLOGIES AND NOVEL PLATFORMS FOR EFFICIENT UPSTREAM AND DOWNSTREAM PROCESSES

1:30 **Scaling Up MSc and EV Production into Bioreactors**

Maya Lim, Regional Account Manager, **RoosterBio Inc.**, *USA*

2:00 **Scale Up Process Development for iPSC Derived Human Immune Cell Therapies**

Wen Bo Wang, SVP, Technical Operations, **Fate Therapeutics**, *USA*

2:30 **Towards fast, accurate and affordable bioprocess control with chip technology**

imec
embracing a better life

Katleen Verleysen, Strategic Partnerships Life Sciences, **IMEC**, *Belgium*

3:00 *Refreshment Break in the Exhibition Hall*

MANUFACTURING AUTOMATION: FROM VEIN TO VEIN

3:30 **Preparing for commercialization – Evolution in Automation Approaches**

- Manual -> modular -> integrated -> step change automation
- COGs should reduce, and industrialization potential should increase
- Finding platforms dedicated to your entire manufacturing process and not just a few process steps
- Flexible systems that can be programmed by end users

Damian Marshall, Director of New Technologies, **Cell and Gene Therapy Catapult**, *UK*

ENHANCED QUALITY & CLINICAL TRIAL RESULTS FOR CAR & T CELL PRODUCTS

4:00 **The Evolving Product Landscape in China – Country Overview**

- A look at recent clinical trial results in the region
- What is the tole between academia & the private sector
- Who is leading the field in China?
- How are manufacturing sites being developed following on from clinical programs

Ting He, CEO, **ImmunoChina Pharmaceuticals Co. Ltd.**, *China*

4:30 **EutilexCo.Ltd. Introduction of Innovative T cell Therapies: 4-1BB Based Autologous T cell Therapy and MVR**

- A look at recent clinical trial results in the region
- What is the tole between academia & the private sector
- Who is leading the field in China?
- How are manufacturing sites being developed following on from clinical programs

Jeonghoon Han Ph.D. (한정훈), Vice President, Chief Technology Officer, Head of R&D Center, **EUTILEX**, *South Korea*

5:00 *End of Day 2 + Evening Networking*

MAIN CONFERENCE • Friday, February 28, 2020

8:15 *Registration*

8:40 **Conference Opening and Welcome**

TRANSITIONING TECHNOLOGIES FROM BENCH TO BEDSIDE: CRISPR, CAS9, GENE THERAPY AND MORE

8:45 **Novel Non-Viral Vector Based CAR-T Platform Development and Progress Update**

Karen Wen, Chief Strategy and Product Development Officer, **GenomeFrontier Therapeutics, Inc.**, *Taiwan*

9:15 **ID Pharma Co., Ltd. Case Study – Sendai Virus**

- Sendai Virus Vector Technology
- Application of Sendai Virus Vector to Cell Engineering and Gene Therapy

Jitsutaro Kawaguchi, Manager, Department of Cell Engineering, **ID Pharma Co., Ltd.**, *Japan*

PRECISION MANUFACTURING PROCESSES – FACILITY CONSIDERATIONS, MONITORING & DESIGN

9:45 **Cell Therapy Manufacturing Commercialization - Strategy and Challenges**

- Unique Manufacturing Challenges for Autologous Cell Therapy
- IND to Commercial: A Paradigm Shift
- Development By Design
- Quality By Design
- Cell Therapy COGs Optimization
- IND to Commercial: Scale-out Challenge
- Cell Therapy Technology Road Map Vision
- Current Weakness in the Technology Landscape
- Final Thoughts

Harry Lam, EVP, Head of Technical Operations, **JW Therapeutics (Shanghai) Co., LTD.**, *China*

10:15 *Morning Coffee and Networking*

WORKING WITH EXTERNAL PARTNERS TO DRIVE COMMERCIALIZATION

11:00 **Overview of the Sumitomo Dainippon Manufacturing Plant for Regenerative Medicine & Cell Therapy – SMaRT**

Kenji Komeda, Senior Director, SMaRT, Regenerative & Cellular Medicine Manufacturing Plant, **Sumitomo Dainippon Pharma Co., Ltd.**, *Japan*

11:30 **DISCUSSION PANEL: Outsourcing vs. Insourcing – What is the best path to take?**

- Looking for 3-5 panellists to join this session that will be looking at:
- Outsourcing models for cell and gene therapies

- Auto vs. allo
- What is the best timeline if you are considering outsourcing?
- When to make the call and make the move?
- Should a CMO be used early phase? Or once you reach submission?
- Why wouldn't you outsource?
- Are there different solutions dependent on product type?
- Does one choice result in a more financially viable product?

David W. Smith, Director, **Healios K.K.**, *Japan*

Jeonghoon Han Ph.D. (한정훈), Vice President, Chief Technology Officer, Head of R&D Center, **EUTILEX**, *South Korea*

Tony Liu, CEO, **Cellular Biomedicine Group**, *China*

Kim Raineri, VP Operations, **Nikon CeLL innovation**, *Japan*

12:00 **Spotlight Presentation**

12:30 *Lunch and Networking*

UPSTREAM AND DOWNSTREAM SUPPLY CHAIN CONSIDERATIONS

2:15 **Perfecting a CAR T Supply Chain What is CAR T Therapy**

- Supply Chain overview, requirement and challenges
- Key Success Factor
- End to End Supply Design and Integration
- Partnership and Collaboration
- Information Technology and Solution
- Next Steps and Action

Naoki Kitadai, CAR T Supply Chain Lead, **Celgene K.K.**, *Japan*

CELL CHARACTERIZATION – QUALITY CONTROL & ANALYTICAL STRATEGIES

2:45 **Critical Quality Attributes & Controls for Cell Therapy Products**

- Case study
- AI/Machine Learning specific case study

Hidenori Nonaka, Group Leader, Regenerative Medicine Research & Planning Division, **Rohto Pharmaceutical Co., Ltd.**, *Japan*

3:15 **Chairperson's Closing Remarks**

3:30 *End of Day 3*



3 EASY WAYS TO REGISTER

ONLINE: informaconnect.com/celltherapy-asia/

CALL: 888-670-8200 or +1.941.554.3500

EMAIL: register@KNect365.com

INDUSTRY	SAVE \$100 USD Register by January 31, 2020	Standard Rate
Main Conference Pass	\$1999 USD	\$2399 USD
Industry Poster Presentation Space	\$200 USD	\$200 USD
ACADEMIC/GOVT.	SAVE \$100 USD Register by January 31, 2020	Standard Rate
Main Conference Pass	\$999 USD	\$1099 USD
Academic Poster Presentation Space	\$150 USD	\$150 USD



REGISTER A GROUP OF 3+ AND SAVE (Industry rates only)

Book your group today: Contact Jess Purnell at Jessica.Purnell@informa.com or +44 (20) 7551 952.

Conference Venue:
The Westin Miyako Kyoto

Kyoto, 605-0052, Japan

Tel: +81-75-771-7111 • Fax: +81-75-751-2490

[Take advantage of our discounted hotel rooms](#)

Sponsors:



Lonza Pharma & Biotech



HIGHLIGHT YOUR PRODUCTS AND SERVICES TO GLOBAL CELL AND GENE THERAPY LEADERS

For sponsorship and exhibit opportunities, contact

Perri Lucatello: Email: Perri.Lucatello@informa.com • Phone: +44 20 7017 7247

Kristin Skahan: Email: Kristin.Skahan@informa.com • Phone: +1-857-208-6639

informaconnect.com/celltherapy-asia/